89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. The company was founded in 2018 and is headquartered in San Francisco, California.
Pegozafermin Promise | Explore 89bio's lead candidate pegozafermin, poised to disrupt MASH and SHTG treatment landscapes with its potential billion-dollar market opportunities |
Clinical Milestones | Delve into 89bio's ongoing Phase 3 trials and the significance of upcoming competitor data in shaping the company's future prospects |
Market Dynamics | Learn how 89bio navigates the evolving MASH treatment landscape, positioning pegozafermin against emerging therapies and potential market shifts |
Financial Outlook | Analyst price targets range from $12 to $49, with potential for significant upside based on clinical outcomes and market positioning |
Metrics to compare | ETNB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipETNBPeersSector | |
---|---|---|---|---|
P/E Ratio | −3.3x | −4.6x | −0.5x | |
PEG Ratio | 0.05 | −0.06 | 0.00 | |
Price/Book | 2.1x | 2.7x | 2.6x | |
Price / LTM Sales | - | 151.9x | 3.3x | |
Upside (Analyst Target) | 210.4% | 191.6% | 43.4% | |
Fair Value Upside | Unlock | 4.9% | 7.1% | Unlock |